FASN and Hyperglycemia: On the other hand, as observed in ob/ob mice, targeting of hepatic FASN in obese individuals may exacerbate hyperglycemia and liver dysfunction, despite an associated amelioration of hepatic steatosis and improvement in glucose tolerance.